Spain's health ministry drafts new drug pricing and funding rules

The Spanish Ministry of Health has circulated a draft law that expands the criteria used to decide public financing and pricing of medicines. Beyond clinical benefit, the proposal requires assessment of therapeutic value, uncertainty, economic impact, and social contribution. It specifies that decisions will consider disease severity, incremental clinical benefit, efficiency, budget impact, innovation, sustainability, and the drug's role in fostering competition. The draft also introduces a “social value” dimension, evaluating how a medication can enhance personal autonomy, social inclusion, and quality of life, especially for people with disabilities or dependence.

In parallel, a Johnson & Johnson‑backed project showcased medicines as social and economic assets, emphasizing their role in generating employment, wealth, and innovation. Experts highlighted the long, costly development process of drugs and argued that their broader societal effects should be treated as a citizen right, urging health systems to guarantee accessibility and equity.

Both initiatives reflect a growing push in Spain to treat pharmaceuticals not only as clinical tools but also as drivers of economic growth and social well‑being.